Advances in™ Schizophrenia: The Role of Emerging Therapies in Improving Safety and Medication Adherence
July 29, 2020
February 10, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
Supported by an educational grant from Alkermes, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — maximum of 1.0 Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
This online educational activity is directed primarily toward psychiatrists. Additional health care professionals involved in patient care of schizophrenia, such as NPs, PAs, and PCPs, will also be invited to participate.
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of schizophrenia, with a forward-looking perspective on how new and novel agents might impact clinical practice. A review of unmet needs related to relapse due to medical nonadherence as well as an exploration of emerging agents that hold promise for overcoming limitations associated with current antipsychotic therapies will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.
Upon completion of this activity, participants should be better able to:
- Recognize unmet needs in schizophrenia treatment and factors that contribute to relapse, including the association between metabolic or other medication adverse effects and treatment nonadherence
- Assess the role of emerging therapies in meeting the unmet needs of patients with schizophrenia based on available efficacy and safety data
- Understand the importance of a comprehensive, holistic, multidisciplinary treatment plan in preventing relapse and improving outcomes in patients with schizophrenia
Christoph U. Correll, MD
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital, Department of Psychiatry
Glen Oaks, NY
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Department of Psychiatry and Molecular Medicine
Investigator, The Feinstein Institutes for Medical Research
Center for Psychiatric Neuroscience
Professor of Child and Adolescent Psychiatry, Charité
Department of Child and Adolescent Psychiatry
René S. Kahn, MD, PhD
Esther and Joseph Klingenstein Professor & Chair
Department of Psychiatry and Behavioral Health System
Icahn School of Medicine at Mount Sinai
New York, NY
VISN 2 Mental Illness Research Education and Clinical Center (MIRECC)
James J. Peters Veterans Affairs Medical Center
Professor of Psychiatry
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Disclosures of Conflicts of Interest
In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Christoph U. Correll, MD
- Grant/Research Support: Janssen, Takeda. Consultant: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva
- Stock/ Shareholder: LB Pharma
René S. Kahn, MD, PhD
- Consultant: Alkermes, Otsuka, Janssen-Cilag, Luye Pharma, Sunovion
The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Complete the activity (including pre- and postactivity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.